DUBLIN, Oct. 11, 2018
/PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today
announced that data regarding the evaluation and rating of
cellulite severity will be presented at the Annual Meeting of the
American Society for Dermatologic Surgery (ASDS) in Phoenix, AZ. Two posters will be on display
October 11th –
October 13th: the first,
an analysis of the Clinician Reported Photonumeric Cellulite
Severity Scale (CR-PCSS) for evaluating cellulite severity; and the
second, an analysis of the potential impact of the gender of a
healthcare provider (HCP) on rating cellulite severity.
One of the two abstract posters to be presented is titled
"Assessing Cellulite Severity: Test-Retest Reliability of and
Concordance between New Clinician Reported and Patient Reported
Photonumeric Scales" and covers the 5-point photonumeric
scales that measure cellulite severity according to the number and
depth of dimples on the evaluated area. Results indicate that the
CR-PCSS is a reliable tool for evaluating cellulite severity of the
buttocks and thighs and correlates well with the Patient Reported
Photonumeric Cellulite Severity Scale. This data was previously
presented at the 2018 International Society for Pharmacoeconomics
and Outcomes Research meeting.
The second abstract poster, titled "Analysis of Potential
Impact of Healthcare Provider Gender on Rating Cellulite
Severity," evaluates the influence of gender on healthcare
providers' perception of cellulite severity. The HCPs rated
female cellulite severity by viewing a set of digital images that
represented the range of cellulite severity on buttocks or thighs.
The results indicate that the gender of a HCP does not appear to
impact assessment of cellulite severity ratings.
"We are pleased that the data from these studies will be
presented at the premier meeting for dermatologic surgeons,"
said Matthew Davis, M.D., R.Ph., Chief Medical Officer, Senior
Vice President, Research and Development, Branded
Pharmaceuticals of Endo Pharmaceuticals. "It is important
that healthcare providers and their patients have a reliable tool
for evaluating cellulite severity. We believe the 5-point
photonumeric scales enable patients and the clinician treating
their cellulite to be aligned during both the informed consent
process prior to treatment, and post treatment when they are
evaluating the outcomes."
About the American Society for Dermatologic Surgery
(ASDS)
The American Society for Dermatologic Surgery
(ASDS) is the largest specialty organization exclusively
representing dermatologic surgeons who have unique training and
experience to treat the health, function and beauty of your skin.
ASDS members are pioneers in the field. Many are involved in the
clinical studies that bring popular treatments to revitalize skin
and fill and diminish wrinkles to the forefront. Their work has
helped create and enhance many of the devices that remove
blemishes, hair and fat, and tighten skin. Dermatologic surgeons
also are experts in skin cancer prevention, detection and
treatment. As the incidence of skin cancer rises, dermatologic
surgeons are committed to taking steps to minimize the
life-threatening effects of this disease. For more information,
visit asds.net.
About Cellulite
Cellulite is a localized
metabolic disorder of tissue under the skin that has been reported
in 85 to 98 percent of post-pubertal females and affects women of
all races and ethnicities[i] [ii]. The condition can
involve the loss of elasticity or shrinking of collagen cords,
called "septae," that attach the skin to the muscle layers below.
When fat in cellulite-prone areas swells and expands, the septae
tether the skin, which causes the surface dimpling characteristic
of cellulite[iii]. Despite multiple therapeutic
approaches for the attempted treatment of cellulite, there are no
FDA-approved pharmacological treatments and little scientific
evidence that any current treatments are
beneficial[iv].
About Endo International plc
Endo International plc
(NASDAQ: ENDP) is a highly focused generics and specialty
branded pharmaceutical company delivering quality medicines to
patients in need through excellence in development, manufacturing
and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters
in Malvern, PA. Learn more at www.endo.com.
Forward Looking Statements
This press release contains certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended, and Canadian securities legislation,
including, but not limited to, the statements by Dr. Davis, and
other statements regarding research and development outcomes,
efficacy, adverse reactions, market and product potential and
product availability. Statements including words such as
"believes," "expects," "anticipates," "intends," "estimates,"
"plan," "will," "may," "look forward," "intend," "guidance,"
"future" or similar expressions are forward-looking statements.
Because these statements reflect Endo's current views,
expectations and beliefs concerning future events, they involve
risks and uncertainties. Although Endo believes that these
forward-looking statements and information are based upon
reasonable assumptions and expectations, readers should not place
undue reliance on them, or any other forward-looking statements or
information in this news release. Investors should note that many
factors, as more fully described in the documents filed
by Endo with the Securities and Exchange
Commission and with securities regulators
in Canada on the System for Electronic Document Analysis
and Retrieval, including under the caption "Risk Factors"
in Endo's Form 10-K, Form 10-Q and Form 8-K filings, and as
otherwise enumerated herein or therein, could
affect Endo's future results and could
cause Endo's actual results to differ materially from
those expressed in forward-looking statements contained in this
communication. The forward-looking statements in this press release
are qualified by these risk factors. Endo assumes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future developments or otherwise, except as may
be required under applicable securities laws.
[i] Avram, Cellulite: a review of its physiology and treatment,
Journal of Cosmetic Laser Therapy 2004; 6: 181–185.
[ii] Khan MH et al. Treatment of cellulite: Part I.
Pathophysiology. J Am Acad Dermatol. 2010
Mar;62(3):361-70.
[iii] Querleux, Anatomy and physiology of subcutaneous adipose
tissue by in vivo MRI and spectroscopy: Relationship with sex and
presence of cellulite, Skin Research and Technology; 8:
118-124.
[iv] Wanner M et al. An evidence-based assessment of treatments
for cellulite. J Drugs Dermatol. 2008 Apr;7(4):341-5.
View original
content:http://www.prnewswire.com/news-releases/endo-presents-data-on-the-perception-and-measurement-of-cellulite-severity-at-the-american-society-for-dermatologic-surgery-asds-annual-meeting-300728834.html
SOURCE Endo International plc